by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Symptoms of advanced myeloproliferative neoplasms (MPN) negatively impact quality of life and include fatigue, night sweats, itching, bone/muscle p......READ MORE
by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP
Achieving durable cytoreduction and adequate symptom relief in patients with polycythemia vera (PV) is a primary treatment challenge. Individual re......READ MORE
First-line hydroxyurea is a therapeutic mainstay for cytoreduction in patients with polycythemia vera (PV); however, not all individuals with PV me......READ MORE
Patients with polycythemia vera (PV) who are nonadherent to cytoreductive and/or antithrombotic therapy are at an increased risk of thrombotic even......READ MORE
Driver mutations correlating with phenotype and prognosis have become increasingly important in predicting clinical outcomes in patients with myelo......READ MORE
Along with age and history of thrombosis, leukocytosis is an independent risk factor for thrombotic events in patients with polycythemia vera (PV).......READ MORE
